IN8bio Inc (INAB) News & EventsINABIN8bio Inc

IN8bio CEO Welcomes New Member and Showcases Progress on TCE Platform

"This quarter we continued to build upon our deep expertise in gammadelta T cells, officially welcoming Dr. Polyakova to the team and making progress with our proprietary TCE platform," said William Ho, CEO and co-founder of IN8bio. "It's also exciting to see the external recognition that the unique properties of gammadelta T cells and their tissue-specific distribution, "may offer a unique opportunity to eliminate pathogenic cells more precisely and deeply in target organs" as stated in the Nature Reviews article. We believe this platform has the potential to enable a new class of therapeutics for autoimmune diseases and oncology, and we are excited to present our initial animal data by year-end."

IN8bio Publishes Clinical Data for INB-200

IN8bio announced the publication of peer-reviewed clinical data from its Phase 1 trial of INB-200 in The Journal of Clinical Oncology. "These peer-reviewed results validate the scientific foundation of our DeltEx platform and highlight the transformative potential of gamma delta T cells in treating solid tumors," said William Ho, CEO and co-founder of IN8bio. "Glioblastoma remains one of the most devastating cancers, and patients urgently need new treatment options. By enabling immune cells to remain active alongside conventional chemotherapy and delivering them directly to the tumor, DeltEx DRI is designed to drive meaningful synergies, improve patient outcomes, and change the treatment paradigm for this disease."

IN8bio Updates Clinical Data for INB-200 and INB-400

IN8bio announced updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 studies at the 2026 American Society of Clinical Oncology, or ASCO, annual meeting. Among patients who received up to six repeat doses of genetically modified gamma delta T cells, median progression-free survival reached 13 months, nearly double the 6.6 months observed in patients receiving standard-of-care alone. mOS has not yet been reached in repeat-dose patients and currently exceeds 19.5 months, compared to a final mOS of 13.2 months for patients receiving only SOC. Approximately 43% of repeat-dose patients remained alive at 24 months versus only 20% of SOC patients. Data are as of the May 15 data cutoff. The studies demonstrated that intracranially delivered DeltEx DRI was generally well tolerated, with no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity events reported. Additional translational analyses integrating histopathology with artificial intelligence technology demonstrated that DeltEx DRI treatment drove a cold-to-hot tumor microenvironment shift, with broad T cell infiltration and reduction in immunosuppressive granulocytes not observed in SOC patients. Repeat DeltEx DRI dosing resulting in higher total doses also increased cumulative T cell and CD4+ levels that correlated significantly with overall survival, linking sustained immune reconstitution to improved outcomes in a dose-dependent manner. Taken together these data point to a T cell-mediated local mechanism with systemic reach.